no BE between early phase and Phase 3 formulations [Regulatives / Guidelines]

posted by fno Homepage – Belgium, 2020-01-22 17:11 (400 d 20:12 ago) – Posting: # 21080
Views: 1,717

Thanks Helmut for your feed-back!

» Without digging into guidelines: No. What we have in Phase I/II is sometimes not what I would call a ‘formulation’ in the biopharmaceutical sense at all. Anything goes: Manually filled capsules, lab-scale tablet-presses, etc.


» Doesn’t matter because we are interested in PK (I) and safety (II).

OK but then how to justify in the dossier the extrapolation of some early phase outcomes, e.g. a food effect or an efficacy and/or safety exposure signal... should these key findings be evaluated/demonstrated again with the final formulation?

» Once you move to phase III you are bound to cGMP (though still in pilot-scale). Only when you move from III to the to be marketed formulation, the applicable SUPAC guidance (IR, MR, SS) cut in and very likely you need a BE study.


Thank you!

Kind regards,

Complete thread:

 Admin contact
21,356 posts in 4,458 threads, 1,493 registered users;
online 9 (0 registered, 9 guests [including 6 identified bots]).
Forum time: Friday 13:23 CET (Europe/Vienna)

Those who make no mistakes are making the biggest mistakes of all 
they are attempting nothing new.    Anthony de Mello

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz